Mayank Bansal, CFA
Mayank Bansal is a CFA Charterholder and heads the Equity Research team at Kapitales Research, with over 5 years of experience analysing global equity markets. He leads fundamental, data-driven research combining rigorous financial analysis with macro trends.
3 ASX Roundup: Retail Impairment, Cardiac AI Growth and Cash-Rich Medtech Updates
Highlights:
Introduction
Late September and October 2026 delivered a busy run of ASX company updates, spanning full-year results, a securities notice and two quarterly activities reports. Myer reported on 23 September and 6 October 2026, while Artrya and Echo IQ both reported on 26 October 2026. Together, they show how an established retailer and two growing medical technology firms are navigating very different conditions.
Stocks in Focus
Artrya Limited
Artrya’s quarterly report, dated 26 October 2026, covered the quarter ended 30 September 2026. After quarter end, Huntsville Hospital Health System signed a five-year agreement worth at least US$0.5 million, becoming Artrya’s largest customer and the first study participant to convert to a commercial contract. Plaque assessments also rose at Tanner Health after a new pre-authorisation workflow launched in mid-September. Cash and term deposits totalled AU$67.2 million, with a AU$4.8 million R&D rebate expected in early 2027. However, an additional reader study has delayed the planned regulatory submission for its coronary flow module.
Myer Holdings Limited
On 23 September 2026, Myer reported results for the 52 weeks to 25 July 2026. Total sales reached AU$4,088.8 million, up 0.7% on a comparable basis, as cost-of-living pressure weighed on the second half. Underlying net profit was AU$42.5 million, but a AU$279.6 million non-cash impairment drove a statutory loss of AU$276.5 million. No final dividend was declared, and net cash stood at AU$100.1 million. A 6 October 2026 notice confirmed that 6,277,563 performance rights and 380,421 share rights lapsed on 29 September 2026.
Echo IQ Limited
In its 26 October 2026 quarterly report, Echo IQ said its EchoSolv AS technology completed 9,697 full-result assessments in the September quarter, about 193% above the prior corresponding period, with year-to-date assessments up roughly 406% to 29,117. Cash was AU$107.8 million after a AU$110 million institutional placement. The US regulator issued a “not substantially equivalent” determination on its heart failure application, but the company lodged an appeal, which was accepted. It also executed agreements with Pro Medicus and Advara HeartCare and appointed Scott Wilkin as a Non-Executive Director.
Outro
The three updates show a market split between caution and growth. Myer is managing a tough consumer backdrop, while both medtech companies are scaling in the US and balancing regulatory hurdles with solid balance sheets. Investors should read the full announcements and seek professional advice before making decisions.
Note: All data presented is based on information available at the time of writing.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au